KRAS and non-small cell lung carcinoma: The description of a biological connection between KRAS and cyclin-dependent kinase (CDK)4/6 was observed in preclinical studies, suggesting that the robust and selective inhibition of CDK4/6 could respond to NSCLC patients carrying KRAS oncogenes [57,58].